IGI Logo

Dishman Carbogen Amcis is currently trading at Rs 212.50, up by 1.75 points or 0.83% from its previous closing of Rs 210.75 on the BSE.

The scrip opened at Rs 215.10 and has touched a high and low of Rs 217.20 and Rs 212.00 respectively. So far 18070 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 2 has touched a 52-week high of Rs 307.80 on 11-Dec-2024 and a 52-week low of Rs 132.75 on 04-Jun-2024.

Last one week high and low of the scrip stood at Rs 217.20 and Rs 206.10 respectively. The current market cap of the company is Rs 3340.26 crore.

The promoters holding in the company stood at 59.32%, while Institutions and Non-Institutions held 10.74% and 29.94% respectively.

Dishman Carbogen Amcis’ wholly owned subsidiary -- Carbogen Amcis’ Shanghai facility has successfully obtained its first Drug Manufacturing License (DML) from China’s National Medical Products Administration (NMPA). The NMPA approval followed a rigorous review focused on GMP compliance and operational readiness. The Shanghai site successfully met all regulatory expectations, reflecting the maturing of its operations and the strength of its quality systems. This milestone marks a pivotal step in Carbogen Amcis’ expansion in China and reinforces its commitment to customers in the region.

Located in the Sanghai Chemical Industry Park (SCIP)h, the 40,000m² site is a fully self-supporting facility equipped for early-phase research and development, pilot scale production and commercial GMP manufacture. Its services range from raw materials to APIs, including high potency material handling and micronization. With equipment in four segregated units and reactor capacities from 50 to 6,300 litres, the facility is built for flexibility, efficiency and scalability. The site employs over 140 people and brings together an international team of specialists whose expertise, combined with advanced infrastructure, enables the delivery of tailored, scalable solutions to customers worldwide.

Dishman Carbogen Amcis (DCAL), incorporated in 1983, started out as a manufacturer of quaternary ammonium and phosphate compounds. Currently, the company is a fully integrated CRAMS player working with global pharmaceutical innovators.